Sight Sciences Highlights OMNI IOP Control and TearCare Superiority at ASCRS 2026
Sight Sciences will present clinical data at the 2026 ASCRS meeting in Washington, DC on its OMNI Surgical System and TearCare System. The OMNI data show significant reductions in long-term diurnal IOP fluctuations regardless of lens status, while TearCare demonstrates early and sustained superiority over Restasis in tear film stability.
1. Clinical Presentations at ASCRS 2026
Sight Sciences will present new data on its OMNI Surgical System and TearCare System at the 2026 ASCRS Annual Meeting in Washington, DC. OMNI data highlight significant reductions in long-term diurnal intraocular pressure fluctuations across lens statuses, while TearCare data demonstrate early and sustained superiority over Restasis in improving tear film stability.
2. Market and Adoption Implications
The durability and versatility of OMNI and the demonstrated clinical benefits of TearCare are expected to support broader adoption by anterior segment surgeons and eyecare providers. These presentations aim to reinforce Sight Sciences’ differentiated positioning in glaucoma and dry eye disease markets, potentially accelerating uptake and informing future commercial strategies.